Table 1.
Demographic, clinical, and transplant-related data of patients with NGM or a GMAa
| Parameter | NGM(n = 252) | GMA(n = 119) | P |
|---|---|---|---|
| Age (yr; mean ± SD) | 47 ± 13 | 54 ± 12 | <0.001 |
| Male gender (%) | 63 | 69 | NS |
| Posttransplantation time (yr; median [range]) | 3.5 (2 to 5) | 4.1 (2.6 to 5.5) | NS |
| Dialysis duration (mo; median [range]) | 18.5 (11 to 35) | 22 (12 to 34) | NS |
| Previous cardiovascular events (%) | 5.4 | 15 | 0.003 |
| Posttransplantation cardiovascular events (%) | 6.3 | 14 | 0.016 |
| HCV (%) | 2.7 | 5.9 | NS |
| Family history of type 2 diabetes (%) | 20 | 29 | 0.069 |
| Current smoker (%) | 16 | 12 | NS |
| CsA (%) | 38 | 44 | NS |
| TAC (%) | 53 | 52 | NS |
| Sirolimus (%) | 11 | 6 | NS |
| CsA levels (ng/ml; mean ± SD) | 126.8 ± 50.7 | 128.4 ± 52.6 | NS |
| TAC levels (ng/ml; mean ± SD) | 8.0 ± 3.0 | 7.9 ± 2.4 | NS |
| MMF (%) | 66 | 62 | NS |
| Corticosteroid withdrawal (%) | 6.8 | 4.2 | NS |
| Prednisone dosage (mg/d; mean ± SD) | 5.23 ± 2.21 | 6.16 ± 2.78 | 0.004 |
| Prednisone dosage >5 mg/d (%) | 19 | 31 | 0.014 |
| Acute rejection (%) | 17 | 18 | NS |
| Creatinine clearance (ml/min; median [range]) | 53 (41 to 69) | 46 (37 to 61) | 0.006 |
| Serum creatinine (mg/dl; median [range]) | 1.34 (1.1 to 1.8) | 1.43 (1.11 to 1.90) | NS |
| Proteinuria (g/24 h; median [range]) | 0.07 (0.01 to 0.18) | 0.06 (0.00 to 0.17) | NS |
| Systolic BP (mmHg; median [range]) | 130 (120 to 140) | 136 (120 to 147) | NS |
| Diastolic BP (mmHg; median [range]) | 80 (74 to 85) | 79 (70 to 84) | NS |
| ≥3 Antihypertensive drugs (%) | 26 | 37 | 0.022 |
| Diuretics (%) | 23 | 34 | 0.023 |
| β Blockers (%) | 33 | 56 | <0.001 |
| Carvedilol (%) | 36 | 41 | NS |
| ACEI/ARB (%) | 52 | 47 | NS |
| Antiplatelet drugs (%) | 27 | 42 | 0.005 |
| Statins (%) | 55 | 64 | NS |
a
GMA include impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and provisional diagnosis of diabetes. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers, CsA, cyclosporin A; GMA, glucose metabolism alteration; HCV, hepatitis C virus; MMF: mycophenolate mofetil; NGM, normal glucose metabolism; TAC, tacrolimus.